early-stage first-in-class non-intoxicating cannabinoid therapeutics
Farbod Parvin
Founder & Chief Executive Officer, THCA Therapeutics
Rheumatoid arthritis remains a large, chronic and growing health burden.
THCA Therapeutics is initially focused on rheumatoid arthritis (RA), a systemic autoimmune disease with measurable inflammatory biology, established development endpoints and substantial unmet need despite multiple approved treatment classes.
people living with RA worldwide
A global disease affecting joints, function, work capacity and quality of life.
of people living with RA are women
The disease burden is disproportionately carried by women.
have moderate or severe disease
WHO reports this population could benefit from rehabilitation services.
projected global prevalence by 2050
A published Global Burden of Disease analysis forecasts continued growth.
global RA therapeutics market
Market estimates vary by methodology; this figure is from Fortune Business Insights.
projected RA therapeutics market
A commercial forecast, not a THCA Therapeutics revenue projection.
Existing therapies can transform outcomes—yet important limitations remain.
THCA PURE™ Oral is not presented as superior to approved medicines. The development objective is to determine whether purified THCA can become a differentiated oral candidate with an interpretable benefit–risk profile for patients who need additional options.
Methotrexate and related agents
- Established first-line role and extensive clinical experience
- Oral or injectable options
- Monitoring for hepatic, hematologic and other toxicities
- Not every patient achieves sufficient disease control
TNF, IL-6 and other targeted biologics
- Established efficacy in moderate-to-severe disease
- Targeted mechanisms and multiple approved options
- Usually administered by injection or infusion
- Infection risk, monitoring and high system cost
JAK inhibitors
- Convenient oral administration
- Established clinical efficacy in selected patients
- Important patient-selection and monitoring requirements
- FDA boxed warnings include serious cardiovascular, cancer, clot and mortality risks
THCA PURE™ Oral
- Intended as a standardized oral pharmaceutical candidate
- Designed around purified THCA in its acidic form
- RA-first, evidence-led development strategy
- Human efficacy, safety, dose and comparative value remain unknown
An oral, non-intoxicating-by-molecule-design development candidate that could occupy a differentiated position if future studies establish reproducible exposure, acceptable safety and clinically meaningful activity.
Validated findings across selected experimental models.
The dashboard below retains the clear progress-bar format while distinguishing quantitative effect estimates, statistically significant directional findings and areas where direct tetrahydrocannabinolic-acid evidence has not yet been established.
Quantitative bar Percentage reported in the paper or transparently estimated from a published figure.
Significance bar The study reports a statistically significant directional result; bar length is not an effect-size percentage.
Evidence-gap bar No validated direct tetrahydrocannabinolic-acid effect size was found for the stated model.
Rheumatoid Arthritis Model
Collagen-induced arthritis in DBA/1 mice · 20 mg/kg/day intraperitoneally · n=9 per group
Approximate percentages are endpoint estimates visually digitized from Figures 5c and 8a, 8b and 8f of Reference 1. They are not exact author-reported effect-size percentages and should be read as approximate comparisons with the untreated CIA group.
Reference 1 ↓Neuroinflammation Model
LPS-activated BV-2 murine microglia and primary mixed glia · 22-hour treatment
The 40–95% nitric-oxide range is stated in Reference 2. The paper reports concentration-dependent iNOS attenuation and a significant TNF-α result in primary glia. Cellular findings do not establish human brain exposure or clinical neuroprotection.
Reference 2 ↓Neurodegeneration Model
3-nitropropionic-acid mouse model of striatal degeneration · 20 mg/kg/day · four days · n=9
Reference 3 reports statistically significant directional findings but does not provide a single text-reported percentage for each endpoint. Hatched bars therefore communicate significance only—not effect magnitude. This was not a 6-OHDA Parkinson’s rat model.
Reference 3 ↓Respiratory Inflammation Model
Future model-selection area for THCA PURE™ Inhale
A frequently cited ovalbumin-asthma paper uses “THCA” as an abbreviation for 3,4,5-trihydroxycinnamic acid, not tetrahydrocannabinolic acid. Other airway-inflammation findings commonly cited in cannabinoid reviews concern CBD. They cannot be presented as direct evidence for THCA PURE™ Inhale.
Respiratory inflammation remains a future hypothesis. Product-specific pulmonary exposure, local tolerability and disease-model effects must be generated in route-appropriate studies.
Reference 4 ↓Further model-level support for biological activity.
These published models broaden the scientific rationale but do not represent active THCA Therapeutics clinical indications.
Rat and house-musk-shrew models
0.05–0.5 mg/kgIntraperitoneal THCA reduced lithium-chloride-induced conditioned gaping in rats and vomiting in house musk shrews. The reported effect was CB1-antagonist-sensitive.
Reference 5 ↓Diet-induced-obesity mouse model
12 weeksPublished THCA-A treatment was associated with reduced adiposity, improved glucose tolerance and insulin sensitivity, and less hepatic steatosis and inflammatory-cell infiltration.
Reference 6 ↓External links open the original journal, PubMed or PubMed Central record. Percentages marked “≈” are approximate figure-derived values.
- Palomares B, et al. (2020). Δ9-Tetrahydrocannabinolic acid alleviates collagen-induced arthritis: Role of PPARγ and CB1 receptors. British Journal of Pharmacology 177:4034–4054. DOI: 10.1111/bph.15155 · PMID: 32510591 · PMCID: PMC7429492
- Sharon N, et al. (2026). Anti-Neuroinflammatory Cannabinoid Acids as a New Therapeutic Approach for Multiple Sclerosis. Molecules 31(7):1227. DOI: 10.3390/molecules31071227 · PMID: 41976267 · PMCID: PMC13074990
- Nadal X, et al. (2017). Tetrahydrocannabinolic acid is a potent PPARγ agonist with neuroprotective activity. British Journal of Pharmacology 174:4263–4276. DOI: 10.1111/bph.14019 · PMID: 28853159 · PMCID: PMC5731255
- Park JW, et al. (2020). 3,4,5-Trihydroxycinnamic acid exerts anti-asthmatic effects in vitro and in vivo. International Immunopharmacology 88:107002. This reference documents that “THCA” in that asthma paper denotes a cinnamic-acid derivative—not tetrahydrocannabinolic acid. DOI: 10.1016/j.intimp.2020.107002 · PMID: 33182035
- Rock EM, et al. (2013). Tetrahydrocannabinolic acid reduces nausea-induced conditioned gaping in rats and vomiting in Suncus murinus. British Journal of Pharmacology 170:641–648. DOI: 10.1111/bph.12316 · PMID: 23889598 · PMCID: PMC3792001
- Palomares B, et al. (2020). Tetrahydrocannabinolic acid A reduces adiposity and prevents metabolic disease caused by diet-induced obesity. Biochemical Pharmacology 171:113693. DOI: 10.1016/j.bcp.2019.113693 · PMID: 31706843
All findings shown are preclinical. They do not establish that THCA PURE™ Oral or THCA PURE™ Inhale is safe, effective, clinically validated or superior to an approved therapy. Animal doses and laboratory concentrations must not be interpreted as human doses.
One focused platform. Two product programs.
THCA PURE™ is the shared pharmaceutical-development platform. It connects qualified materials, analytical methods, controlled manufacturing, formulation development, packaging, regulatory planning and future clinical evidence.
Purified THCA · shared quality framework · evidence-led translation
THCA PURE™ Oral
The current priority: a standardized oral pharmaceutical candidate for staged investigation in chronic inflammatory disease, beginning with rheumatoid arthritis.
- Lead indication
- Rheumatoid arthritis
- Intended setting
- Controlled chronic dosing
- Current stage
- Candidate and prototype preparation
- Evidence status
- Published rationale; product validation pending
THCA PURE™ Inhale
A future inhaled-delivery program intended to evaluate rapid and controlled pulmonary exposure after the oral program’s core development priorities are adequately resourced.
- Strategic role
- Second platform product
- Delivery objective
- Rapid, standardized exposure
- Current stage
- Future development concept
- Evidence status
- Route-specific validation not established
Material qualification
Identity, purity, impurities and supply-chain control.
Analytical development
Assay, degradation, release and bioanalytical methods.
Controlled manufacturing
Phase-appropriate process definition and quality oversight.
Stability & packaging
Evidence-led protection from relevant environmental stress.
Regulatory translation
CMC, nonclinical and clinical packages built around decision gates.
This page intentionally describes the platform and product programs without publishing confidential composition, process parameters, supplier specifications or claim-development details.
The aim is a differentiated profile—not an unsupported superiority claim.
Approved therapies have established benefit–risk profiles based on human trials and real-world use. THCA PURE™ Oral must earn its position through product-specific formulation, safety, pharmacokinetic and clinical data.
| Therapy class | Administration | Clinical status | Key established strength | Important trade-off / unknown |
|---|---|---|---|---|
| Conventional DMARDsMethotrexate, leflunomide, others | Oral / injection | Approved | First-line experience, accessibility and disease modification | Monitoring, tolerability and incomplete response in some patients |
| Biologic DMARDsTNF, IL-6 and other targets | Injection / infusion | Approved | Targeted and clinically validated treatment options | Infection risk, administration burden and high cost |
| JAK inhibitorsTargeted synthetic DMARDs | Oral | Approved | Oral targeted therapy with established efficacy | Serious safety warnings and careful patient selection |
| THCA PURE™ OralPurified-THCA candidate | Oral · intended | Investigational | Potential non-intoxicating, differentiated oral profile | Human exposure, safety, efficacy and comparative value unestablished |
Progress is measured by evidence packages—not calendar promises.
The program advances only when the preceding technical and regulatory questions have been answered sufficiently. Current public status is shown below; future milestones remain contingent on data, financing and approvals.
Lead indication, platform strategy and evidence boundary established.
Materials, analytics, prototype feasibility and partner engagement.
Compatibility, stability, release and candidate-selection data.
Strategic definition
- Rheumatoid arthritis selected as lead indication
- THCA PURE™ platform and two-product focus defined
- Published-evidence dossier assembled
- Preliminary prior-art and IP assessment documented
Materials & analytics
- Company and operating setup
- Scientific, CMC and regulatory network build
- Supplier and material qualification planning
- Analytical and prototype-development preparation
Prototype feasibility
- Manufacturing feasibility and initial prototypes
- Product integrity and reproducibility
- Initial release and quality testing
- Prototype selection or redesign decision
Candidate selection
- Comparative compatibility and stability signals
- Packaging and release performance
- Candidate specification and process definition
- Data-supported IP filing decisions
CTA-enabling readiness
- Phase-appropriate CMC package
- Nonclinical and bioanalytical program
- Regulatory scientific advice
- GMP clinical-batch pathway
Human translation
- First-in-human safety and pharmacokinetics
- Dose and exposure interpretation
- Exploratory RA patient study
- Advance, redesign, partner or discontinue decision
Transform an underexplored cannabinoid acid into a rigorously evaluated pharmaceutical platform.
THCA Therapeutics aims to build a specialized biotechnology company recognized for scientific discipline, transparent evidence standards and responsible clinical translation—starting with rheumatoid arthritis and expanding only when data justify the next program.
Ask a precise question and generate evidence capable of answering it.
Separate published findings, company data, hypotheses and future plans.
Build differentiated products through formulation, quality and clinical execution.
Pursue development only where a meaningful therapeutic contribution is plausible.
THCA Therapeutics is a Munich-based biotechnology business operated by Farbod Parvin as a sole proprietor. THCA PURE™ Oral and THCA PURE™ Inhale are investigational development concepts and are not approved for medical or commercial use. No product-specific human efficacy, safety, stability, bioavailability, patent protection or freedom-to-operate conclusion is claimed.
